Ignacio Melero, MD, PhD
Patients with advanced hepatocellular carcinoma (HCC) had objective responses (OR) and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.
In the dose-expansion phase, a subgroup of 69 patients without exposure to sorafenib had an objective response rate of 21.7% (all partial response). An additional 43.5% of patients had stable disease. Survival at 6 and 9 months were 87% and 77%, respectively, Melero reported.
Melero I, Sangro B, Yau T, et al. Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma: the CheckMate 040 study. Abstract presented at: 2017 Gastrointestinal Cancers Symposium; January 19-21, 2017; San Francisco, CA.
... to read the full story